Excise valuation of captive bulk drugs: DPCO price prevails over cost construction when comparable sales exist.

Excise valuation of captively consumed bulk drugs must follow the prescribed sequence of valuation rules, and a comparable DPCO price cannot be displaced by cost construction under Rule 6(b)(ii) unless the preceding methods are first ruled out. Where similar goods are sold at the DPCO price, that price is the relevant comparable basis for valuation. The text also notes that prior departmental acceptance of the same valuation basis weakens any allegation of suppression, so an extended limitation period may not be available. If the demand is time-barred and unsustainable on merits, penalty and interest also do not survive.

---

---

Issues: (i) Whether the assessable value of bulk drugs captively consumed during the relevant period had to be determined on the basis of the DPCO price or on cost construction under the valuation rules. (ii) Whether the demand was barred by limitation and, if so, whether penalty and interest could survive.

Issue (i): Whether the assessable value of bulk drugs captively consumed during the relevant period had to be determined on the basis of the DPCO price or on cost construction under the valuation rules.

Analysis: The show cause notice proceeded on captive consumption and on the declared DPCO price as the assessable value. The record also showed that the same bulk drug had been assessed earlier on the basis of the DPCO price, indicating departmental awareness of that basis of valuation. The finding that sales were to a related person and that cost construction under Rule 6(b)(ii) was necessary could not be sustained because the notice itself did not allege such a factual foundation. Where similar goods were being sold by the assessee and other manufacturers at the DPCO price, that price constituted the comparable price and Rule 4 had to be considered before resorting to Rule 6(b)(ii). Valuation provisions had to be applied in sequence, and the adjudicating authority could not bypass the comparison rule.

Conclusion: The assessable value could not be fixed on cost construction under Rule 6(b)(ii); the DPCO price was the relevant comparable price. The valuation demand failed.

Issue (ii): Whether the demand was barred by limitation and, if so, whether penalty and interest could survive.

Analysis: The notice was issued long after the relevant period, and the materials on record showed that the department had earlier raised and accepted a demand on the same bulk drug on the basis of DPCO price. In that background, the allegation of suppression was not made out. Once the demand itself could not be sustained on merits and the notice was time-barred, the foundation for penalty and interest also disappeared.

Conclusion: The demand was barred by limitation, and the penalty and interest were not sustainable.

Final Conclusion: The impugned order was set aside and the appeal succeeded in full.

Ratio Decidendi: In excise valuation, the prescribed rules must be applied seriatim and the comparable market price cannot be displaced by cost construction unless the preceding valuation methods are first ruled out; where the department had prior knowledge of the valuation basis, the extended period for suppression is not available.

---